Hurimbiocell

Hurim BioCell is a South Korean biotechnology company specializing in the development of regenerative medicines using adipose-derived mesenchymal stem cells (ADSCs). Established in 2005, the company focuses on treating chronic and intractable diseases through its proprietary cell isolation and mass-culture technologies. Its clinical pipeline includes HB-101, a treatment for liver cirrhosis currently in Phase 2 trials, and HB-201, a therapy for androgenetic alopecia in Phase 1. Hurim BioCell operates a state-of-the-art GMP-certified facility to ensure the production of high-quality cell therapies. By integrating automation technology from its affiliate, Hurim Robot, the company aims to standardize and scale the manufacturing of stem cell products. Hurim BioCell is positioned as a leader in the Korean regenerative medicine sector, targeting significant unmet needs in hepatology and dermatology.